Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASP8273 Rollover Study
NCT03042013Phase 2Withdrawn
- Sponsor
- Astellas Pharma
- Start
- Feb 2017
- Primary completion
- Feb 2017
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of naquotinib in non-small cell lung cancer (NSCLC), sponsored by Astellas Pharma. Primary endpoints: Incidence of adverse events and Number of participants with laboratory value abnormalities. Planned start Feb 2017; status: withdrawn.
02
Drugs
naquotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03042013.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03042013.